Revaprazan - Misplaced Pages

Medication used to treat gastritis Pharmaceutical compound

Revaprazan
Clinical data

Trade names	Revanex
Other names	YH1885
ATC code	None
Identifiers
IUPAC name N-(4-Fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-2-pyrimidinamine
CAS Number	199463-33-7
PubChem CID	204104
ChemSpider	176801
UNII	5P184180P5
CompTox Dashboard (EPA)	DTXSID10870216
Chemical and physical data
Formula	C₂₂H₂₃FN₄
Molar mass	362.452 g·mol
3D model (JSmol)	Interactive image
SMILES c1cc(F)ccc1Nc2nc(C)c(C)c(n2)N3CCc4ccccc4C3C
InChI InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26) Key:LECZXZOBEZITCL-UHFFFAOYSA-N

Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in South Korea, but is not approved in Europe or the United States.

References

"Revaprazan". drugs.com.
Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol. 25 (10): 1618–1625. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169. S2CID 41932174.
Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol. 44 (1): 73–82. doi:10.1177/0091270003261321. PMID 14681344. S2CID 19658496.
"Revaprazan Yuhan registered, South Korea (gastritis)". R & D Focus Drug News. September 25, 2006. Archived from the original on April 29, 2014.

v t e Drugs for peptic ulcer and GERD/GORD (A02B)
H₂ antagonists ("-tidine")	Cimetidine Famotidine Lafutidine Lavoltidine (loxtidine) Niperotidine Nizatidine Ranitidine Roxatidine
Prostaglandins (E)/ analogues ("-prost-")	Misoprostol Enprostil
Proton-pump inhibitors ("-prazole")	Anaprazole Azeloprazole Dexlansoprazole Dexrabeprazole Esomeprazole Ilaprazole Lansoprazole Omeprazole Pantoprazole Picoprazole Rabeprazole Tenatoprazole Timoprazole
Potassium-competitive acid blockers ("-prazan")	Fexuprazan Linaprazan Revaprazan Soraprazan Tegoprazan Vonoprazan Zastaprazan
Others	Aceglutamide aluminum Acetoxolone Alginic acid Arbaclofen placarbil Bismuth subcitrate Carbenoxolone Cetraxate Gefarnate Irsogladine Lesogaberan Pirenzepine Proglumide Rebamipide Sucralfate Sulglicotide Telenzepine Teprenone Troxipide Zinc L-carnosine Zolimidine
Combinations	Bismuth subcitrate/metronidazole/tetracycline Omeprazole/amoxicillin/rifabutin Vonoprazan/amoxicillin Vonoprazan/amoxicillin/clarithromycin
See also: Helicobacter pylori* eradication protocols*
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories:

See also

References